180 related articles for article (PubMed ID: 38441626)
1. Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
Dilli Batcha JS; Gota V; Matcha S; Raju AP; Rao M; Udupa KS; Mallayasamy S
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38441626
[TBL] [Abstract][Full Text] [Related]
2. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia.
Corral Alaejos Á; Zarzuelo Castañeda A; Jiménez Cabrera S; Sánchez-Guijo F; Otero MJ; Pérez-Blanco JS
Br J Clin Pharmacol; 2022 Feb; 88(4):1913-1924. PubMed ID: 34705297
[TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
4. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
[TBL] [Abstract][Full Text] [Related]
5. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.
Zhou L; Meng F; Yin O; Wang J; Wang Y; Wei Y; Hu P; Shen Z
Clin Ther; 2009 Jul; 31(7):1568-75. PubMed ID: 19695406
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration-Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia.
Adawi DH; Fredj NB; Al-Barghouthi A; Dridi I; Lubada M; Manasra M; Aouam K
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):43-55. PubMed ID: 38006575
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
9. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
12. [The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Shen HJ; He J; Qiu QC; Cen JN; Pan JL; Yao L; Ding ZX; Chen Y; Chen ZX
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):21-5. PubMed ID: 23597459
[TBL] [Abstract][Full Text] [Related]
13. Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.
Matcha S; Dillibatcha J; Raju AP; Chaudhari BB; Moorkoth S; Lewis LE; Mallayasamy S
Paediatr Drugs; 2023 May; 25(3):365-375. PubMed ID: 36943583
[TBL] [Abstract][Full Text] [Related]
14. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
15. New strategies in controlling drug resistance.
Frame D
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Jabbour E; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Whiteley J; Iyer S; Candrilli SD; Kaye JA
Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
20. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
